Chemoradiotherapy: Emerging treatment improvement strategies

Head and Neck

Volumn 25, Issue 2, 2003, Pages 152-167

  Milas, Luka ^a   Mason, Kathryn A ^a   Liao, Zhongxing ^b   Ang, Kian K ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemoradiation; Molecular targeting; Nucleoside analogs; Taxanes

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ALKALOID; ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETOPOSIDE; FLUDARABINE; GEMCITABINE; LOMUSTINE; MITOMYCIN C; NITROSOUREA DERIVATIVE; NUCLEOSIDE ANALOG; PACLITAXEL; POLYGLUTAMIC ACID; TAXANE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

BLOOD TOXICITY; CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CELL REGENERATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ESOPHAGUS DISEASE; HEAD AND NECK CANCER; HUMAN; LUNG TOXICITY; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; TUMOR CELL;

EID: 0037304502     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10232     Document Type: Review

References (94)

1. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-1598.
2. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
3. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-1143.
4. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
5. Phillips TL. Radiation-chemotherapy interactions. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, editors. Lung cancer: principles and practice. Philadelphia: Lippincott-Raven Publishers; 1996.
6. Tannock I. The basic science of oncology. Tannock IF, Hill RP, editors. New York: McGraw-Hill, Health Professions Division; 1998.
7. Herscher LL, Cook JA, Pacelli P, Pass HI, Russo A, Mitchell JB. Principles of chemoradiation: theoretical and practical considerations. Oncology 1999;13(10 Suppl 5): 11-22.
8. Radford IR. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after x-irradiation of mammalian cells. Int J Radiat Biol 1986;49:611.
9. Kinsella TJ, Dobson PP, Mitchell JB, Fornace AJ, Jr. Enhancement of X ray induced DNA damage by pretreatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 1987;13:733-739.
10. Wang Y, Pantelias GE, Iliakis G. Mechanism of radiosensitization by halogenated pyrimidines: the contribution of excess DNA and chromosome damage in BrdU radiosensitization may be minimal in plateau-phase cells. Int J Radiat Biol 1994;66:133-142.
11. Elkind MM, Sutton HF. X-ray damage and recovery in mammalian cells in culture. Nature 1959;184:1293.
12. Little JB, Hahn GM, Frindel E, Tubian M. Repair of potentially lethal radiation damage in vitro and in vivo. Radiology 1973;106:689.
13. Terasima T, Tolmach LJ. Variations in survival responses of HeLa cells to x-irradiation during the division cycle. Biophys J 1963;3:11-33.
14. Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992;52:3495-3497.
15. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999;9:12-26.
16. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24: S-7, 24-S7, 28.
17. Milas L, Fuji T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999; 59:107-114.
18. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-1416.
19. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45.
20. Nordsmark M, Overgard M, Overgard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;4:31.
21. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-289.
22. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995;55:3564-3568.
23. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-6465.
24. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49: 4373-4384.
25. Hermens AF, Barendsen GW. The proliferative status and clonogenic capacity of tumour cells in a transplantable rhabdomyosarcoma of the rat before and after irradiation with 800 rad of X-rays. Cell Tissue Kinet 1978;11: 83-100.
26. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-146.
27. Milas L, Yamada S, Hunter N, Guttenberger R, Thames HD. Changes in TCD50 as a measure of clonogen doubling time in irradiated and unirradiated tumors. Int J Radiat Oncol Biol Phys 1991;21:1195-1202.
28. Saunders MI, Dische S, Rojas A. CHART (continuous, hyperfractionated, accelerated radiotherapy): a tale of two disciplines. Br J Cancer 1999;80(Suppl 1):110-115.
29. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
30. Durand RE, Vanderbyl SL. Tumor resistance to therapy: a genetic or kinetic problem? Cancer Commun 1989;1: 277-283.
31. Stephens TC, Peacock JH. Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Br J Cancer 1977;36:313-321.
32. Milas L, Nakayama T, Hunter N, et al. Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. Radiother Oncol 1994;30: 247-253.
33. Bourhis J, Wilson G, Wibault P, et al. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 1994;104:468-472.
34. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Nat Cancer Inst 1991;83:417-423.
35. Sause W, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Nat Cancer Inst 1995;87:198-205.
36. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88: 1210-1215.
37. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326:524-530.
38. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995;13:452-458.
39. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-1070.
40. Wagner H, Jr. Rational integration of radiation and chemotherapy in patients with unresectable stage IIIA or IIIB NSCLC. Results from the Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Therapy Oncology Group. Chest 1993;103:35S-42S.
41. Sause WT, Scott C, Taylor S, et al. Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer. Radiation Therapy Oncology Group 88-04. Am J Clin Oncol 1992;15:163-167.
42. Dillman R, Seagren S, Propert K, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-945.
43. Dillman R, Seagren S, Herndon J, Greer M. Randomized trial of induction chemotherapy plus radiation versus radiation alone in stage III non-small cell lung cancer: five year follow-up of CALGB. Proc Am Soc Clin Oncol 1993; 12:329.
44. Curran W, Jr, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for PTS with unresected Stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. ASCO Proceedings 484a, 2000.
45. Komaki R, Scott C, Sause W, et al. Induction cisplatin/ vinblastine decreased distant metastasis in unresectable squamous cell lung cancer (SCC): failure patterns in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys 1997;39:537-544.
46. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-955.
47. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-1324.
48. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Nat Cancer Inst 1999;91:2081-2086.
49. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I. Preclinical experience. Anticancer Drugs 1995;6:339-355, 363-368.
50. Minarik L, Hall EJ. Taxol in combination with acute and low dose rate irradiation. Radiother Oncol 1994;32: 124-128.
51. Hennequin N, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronized HeLa cells. Br J Cancer 1995;71:1194-1198.
52. Milas L. Docetaxel-radiation combinations: rationale and preclinical findings. Clin Lung Cancer 2002;3(Suppl 2):S29-S36.
53. Milas L, Mason K, Milas M. Docetaxel and radiation in lung cancer: preclinical investigations. Adv Lung Cancer 2001;3:6-8.
54. Milross CG, Mason KA, Hunter NR, et al. Enhanced radioresponse of paclitaxel-sensitive and -resistant tumors in vivo. Eur J Cancer 1997;33:1299-1308.
55. Mason KA, Kishi K, Hunter N, et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999;5:4191-4198.
56. Choy H, MacRae R. The current state of paclitaxel and radiation in the combined-modality therapy of non-small cell lung cancer. Semin Oncol 2001;28:17-22.
57. Mauer AM, Masters GA, Haraf DJ, et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998;16:159-164.
58. Koukourakis MI, Bahlitzanakis N, Froudarakis M, et al. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br J Cancer 1999;80:1792-1796.
59. Choy H, DeVore RF, Hande KR, et al. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer 2001;34:441-449.
60. McGinn, CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst 1996;88:1193-1203.
61. McGinn CJ, Lawrence TS. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 2001; 11:270-280.
62. Gregoire V, Van NT, Stephens LC, et al. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 1994;54:6201-6209.
63. Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999;44:1125-1135.
64. Gregoire V, Hittelman WN, Rosier JF, Milas L. Chemoradiotherapy: radiosensitizing nucleoside analogues. Oncol Rep 1999;6:949-957.
65. Gregoire V, Ruifrok ACC, Price RE, et al. Effect of intraperitoneal fludarabine administration on rat spinal cord tolerance to fractionated irradiations. Radiother Oncol 1995;36:50-55.
66. Scalliet P, Goor C, Galdermans D, et al. Gemzar (gemcitabine) with thoracic radiotherapy - a phase II pilot study in chemonaive patients with advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998; 17:499a.
67. Fossella F, Zinner RG, Komaki R, et al. Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): a phase I trial for patients with stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:312a.
68. Vokes EE, Leopold KA, Herndon II, et al. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (IndCT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB Study 9431). Proc Am Soc Clin Oncol 1999;18:459A.
69. Gregoire V, Ang KK, Rosier JF, et al. A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. Radiother Oncol 2002;63:187-193.
70. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19:792-799.
71. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992;3:351-362.
72. Li C, Newman RA, Wu QP, et al. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol 2000;46:416-422.
73. Li C, Price JE, Milas L, et al. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 1999;5:891-897.
74. Li C, Ke S, Wu QP, et al. Potentiation of ovarian OCa-1 tumor radioresponse by poly (L-glutamic acid)-paclitaxel conjugate. Int J Radiat Oncol Biol Phys 2000;48: 1119-1126.
75. Li C, Ke S, Wu QP, et al. Tumor irradiation enhances the tumor-specific distribution of poly(L- glutamic acid)conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 2000;6:2829-2834.
76. Mason K, Hunter NR, Wallace S, Milas L. Poly (L-glutamic acid)-paclitaxel dramatically enhances the antitumor efficacy of radiotherapy. Clin Cancer Res 2001;7: 769.
77. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-2707.
78. Mason KA, Komaki R, Cox JD, Milas L. Biology-based combined-modality radiotherapy: workshop report. Int J Radiat Oncol Biol Phys 2001;50:1079-1089.
79. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001;11:290-299.
80. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-2890.
81. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6: 701-708.
82. Nasu S, Ang KK, Fan Z, Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001;51:474-477.
83. Nasu S, Hunter NR, Mason KA, Fan Z, Ang KK, Milas L. C225 antiepidermal growth factor receptor (EGFR) antibody enhances human tumor xenograft response to radiation (XRT) and docetaxel (DOC) [Abstract]. Program and Abstracts from the Forth-eighth Annual Meeting of the Radiation Research Society; 2001. p 169.
84. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59: 1935-1940.
85. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-2174.
86. Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000;6: 4343-4350.
87. Koki A, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Invest Drugs 1999;8:1623-1638.
88. Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ. Enhancement of tumor response to g-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Nat Cancer Inst 1999;91:1501-1504.
89. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326-1331.
90. Petersen C, Petersen S, Milas L, Lang FF, Tofilon P. Human glioma cell radiosensitization by a selective COX-2 Inhibitor. Clin Cancer Res 2000;6:2513-2520.
91. Davis T, Hunter N, Trifan OC, Milas L. COX-2 Inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol. In Press.
92. Dicker AP, Williams TL, Grant DS. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 2001;24:438-442.
93. Milas L, Hanson WR. Eicosanoids and radiation. Eur J Cancer 1995;31A:1580-1585.
94. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.